0000059478-19-000322.txt : 20191217 0000059478-19-000322.hdr.sgml : 20191217 20191217084642 ACCESSION NUMBER: 0000059478-19-000322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20191217 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191217 DATE AS OF CHANGE: 20191217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 191288646 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 a8-k2020guidancedecemb.htm 8-K Document
false0000059478 0000059478 2019-12-17 2019-12-17 0000059478 us-gaap:CommonClassAMember 2019-12-17 2019-12-17 0000059478 lly:A625Notesdue2031Member 2019-12-17 2019-12-17 0000059478 lly:A1.625NotesDueJune22026Member 2019-12-17 2019-12-17 0000059478 lly:A1.700Notesdue2049Member 2019-12-17 2019-12-17 0000059478 lly:A2.125NotesDueJune32030Member 2019-12-17 2019-12-17 0000059478 lly:A718NotesDueJune12025Member 2019-12-17 2019-12-17 0000059478 lly:A6.77NotesDueJanuary12036Member 2019-12-17 2019-12-17 0000059478 lly:A1.000NotesDueJune22022Member 2019-12-17 2019-12-17


  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
________________
FORM 8-K 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
________________

Date of report (Date of earliest event reported): December 17, 2019 
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in Charter) 
  
 
 
 
 
Indiana
 
001-06351
 
35-0470950
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
 

Lilly Corporate Center
Indianapolis, Indiana 46285
(Address of Principal Executive Offices, and Zip Code)

(317) 276-2000
Registrant’s Telephone Number, Including Area Code

Not Applicable
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
 
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
 
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
 
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock (no par value)
LLY
New York Stock Exchange
1.000% Notes due 2022
LLY22
New York Stock Exchange
7 1/8% Notes due 2025
LLY25
New York Stock Exchange
1.625% Notes due 2026
LLY26
New York Stock Exchange
2.125% Notes due 2030
LLY30
New York Stock Exchange
0.625% Notes due 2031
LLY31
New York Stock Exchange
6.77% Notes due 2036
LLY36
New York Stock Exchange
1.700% Notes due 2049
LLY49A
New York Stock Exchange





Item 2.02. Results of Operations and Financial Condition

On December 17, 2019, the Company issued a press release updating financial guidance for 2019, reaffirming financial expectations through the remainder of the decade, and announcing financial guidance for 2020. In addition, on the same day, the Company held a teleconference for analysts and media to discuss this guidance. The teleconference was web cast on the Company's web site. The press release is attached to this Form 8-K as Exhibit 99.1.

The Company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP), and the attached press release includes a description of certain non-GAAP items that may affect our financial expectations for 2019 and 2020. The Company’s non-GAAP financial measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the Company’s reported operations for a period. The Company believes that these non-GAAP financial measures provide useful information to investors. Among other things, they may help investors evaluate the Company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP financial measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP financial measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.



Item 9.01. Financial Statements and Exhibits

Exhibit Number    
Description
104
Cover page interactive data file (embedded within the Inline XBRL document)








SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:     /s/ Donald A. Zakrowski    
Name: Donald A. Zakrowski
Title:     Vice President, Finance and Chief Accounting Officer

Dated: December 17, 2019



 EX-99.1 2 lilly2020financialguid.htm EXHIBIT 99.1 Exhibit
lilly2020financialgui_image1.gif

December 17, 2019
    





For Release:        Immediately
Refer to:
Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)
Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)

Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance

•
Lilly expects 2020 to be a strong year of financial and operational performance, characterized by robust top-line growth, margin expansion, continued pipeline progress and solid cash flow.
•
2020 revenue is expected to be between $23.6 billion and $24.1 billion, driven by volume growth from key growth products, including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, Emgality, Baqsimi and Reyvow.
•
Operating margin is expected to be 31 percent on a non-GAAP basis in 2020.
•
Earnings per share (EPS) for 2020 are expected to be in the range of $6.38 to $6.48 on a reported basis and $6.70 to $6.80 on a non-GAAP basis.
•
Meeting its 2020 revenue and operating margin forecasts would allow the company to achieve or exceed the targets it previously communicated for the time period 2015 – 2020.
•
Continued pipeline progress in 2020 will include important data readouts for several investigational medicines, the possibility for two regulatory approvals, and up to three new launches.
•
The company now expects 2019 EPS to be in the range of $8.57 to $8.67 on a reported basis. On a non-GAAP basis, the company has reaffirmed 2019 EPS to be in the range of $5.75 to $5.85.

INDIANAPOLIS, IN - Eli Lilly and Company (NYSE: LLY) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, which are expected to result in operating margin expansion and strong earnings performance. The company also revised certain elements of its 2019 financial guidance and reviewed potential key events for the upcoming year, including important data readouts for several investigational medicines in its clinical pipeline, the possibility for two regulatory approvals, and up to three new launches in 2020.

Josh Smiley, Lilly’s chief financial officer, outlined the company’s near-term growth prospects and provided 2020 financial guidance. “We expect 2020 to be a year of strong operating and financial performance for Lilly, characterized by revenue growth for our key medicines both in the U.S. and in international markets, ongoing productivity initiatives leading to further margin expansion, continued progress in our clinical pipeline of new medicines, and solid cash flow.” said Smiley. “We are confident in our ability to deliver on our 2020 expectations, and thereby achieve or exceed the financial and pipeline commitments we had previously made for the period 2015-2020.”

Commenting on the company’s cash flow expectations, Smiley added, “Our robust financial performance is expected to generate strong cash flow, which we will continue to deploy thoughtfully. Our capital allocation priorities remain unchanged, starting with funding our promising pipeline and our recently launched medicines, then leveraging business development to access additional external innovation opportunities, followed by returning cash to shareholders through our recently-increased dividend and our ongoing share repurchase program.”

“Lilly is in the early phase of an exciting period of prolonged growth for the company, driven by an expanding portfolio of new medicines focused on diabetes, oncology, immunology, and neuroscience,” said David A. Ricks, Lilly’s chairman and chief executive officer. “With an attractive commercial portfolio and limited patent exposure through the latter half of the upcoming decade, we are well positioned to deliver sustainable volume-based revenue growth and drive further operating margin expansion. As we continue to invest in our innovation-based strategy, we are confident in our ability to discover and develop important new medicines for patients.”

2019 Financial Guidance
The company has updated certain elements of its 2019 financial guidance. On a reported basis, earnings per share for 2019 are now expected to be in the range of $8.57 to $8.67. The decrease in expected earnings per share on a reported basis is due to a net charge related to the repurchase of debt, and additional asset impairment, restructuring, and other special charges related to global cost reduction initiatives, largely offset by a gain on the sale of the company’s antibiotics business in China. On a non-GAAP basis, earnings per share for 2019 are still expected to be in the range of $5.75 to $5.85.

 
2019
Expectations
% Change from 2018
Earnings per share (reported)
$8.57 to $8.67
NM
Discontinued operations
(3.930)
 
Earnings per share from continuing operations (reported)
$4.64 to $4.74
52% to 55%
Asset impairment, restructuring and other special charges
.58
 
Amortization of intangible assets
.18
 
Lartruvo charges
.14
 
Acquired in-process research and development
.21
 
Gain on sale of China antibiotics business
(.27)
 
Net charge related to repurchase of debt
.21
 
Impact of reduced shares outstanding for non-GAAP reporting
.07
 
Earnings per share (non-GAAP)
$5.75 to $5.85
6% to 8%
NM – not meaningful; Numbers may not add due to rounding

 
 

The following table summarizes the company’s 2019 financial guidance:
 
2019 Guidance
 
Prior
 
Updated
Revenue
$22.0 to $22.5 billion
 
Unchanged
 
 
 
 
Gross Margin % of Revenue (reported)
Approx. 79%
 
Unchanged
Gross Margin % of Revenue (non-GAAP)
Approx. 80%
 
Unchanged
 
 
 
 
Marketing, Selling & Administrative
$5.9 to $6.1 billion
 
Unchanged
 
 
 
 
Research & Development
$5.5 to $5.7 billion
 
Unchanged
 
 
 
 
Other Income/(Expense) (reported)
$(100) to $50 million
 
$(35) to $115 million

Other Income/(Expense) (non-GAAP)
$(100) to $50 million
 
Unchanged

 
 
 
 
Tax Rate (reported)
13.0% to 14.0%
 
Unchanged
Tax Rate (non-GAAP)
12.0% to 13.0%
 
Unchanged
 
 
 
 
Earnings per share (reported)
$8.59 to $8.69
 
$8.57 to $8.67
Earnings per share (non-GAAP)
$5.75 to $5.85
 
Unchanged
 
 
 
 
 
 
 
 
Non-GAAP guidance reflects adjustments presented in the earnings per share table above.


2020 Financial Guidance
The company today issued its 2020 financial guidance. Earnings per share for 2020 are expected to be in the range of $6.38 to $6.48 on a reported basis and $6.70 to $6.80 on a non-GAAP basis. Non-GAAP earnings per share for 2020 exclude amortization of intangible assets.

 
2020 Expectations
 
Earnings per share (reported)
$6.38 to $6.48
 
Amortization of intangible assets
.32
 
Earnings per share (non-GAAP)
$6.70 to $6.80
 

Numbers may not add due to rounding

The company anticipates 2020 revenue between $23.6 billion and $24.1 billion. Meeting its 2020 revenue forecast would allow the company to achieve or exceed the 7 percent revenue CAGR target it previously communicated for the time period 2015 – 2020. Revenue growth is expected to be driven by volume from key growth products including Trulicity®, Taltz®, Basaglar®, Jardiance®, Verzenio®, Cyramza®, Olumiant®, Emgality®, BaqsimiTM, and the expected launch of ReyvowTM. Revenue growth could also benefit from the potential launch of other new medicines. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity, including the expected entry of generic competition for Forteo® in the U.S. Revenue growth is also expected to be partially offset by a low-single digit net price decline in the U.S. driven primarily by rebates and legislated increases to Medicare Part D cost sharing, patient affordability programs, and net price declines in China, Japan and Europe.

Gross margin as a percent of revenue rate is expected to be approximately 79 percent on a reported basis, and approximately 81 percent on a non-GAAP basis.

Marketing, selling and administrative expenses are expected to be in the range of $6.1 billion to $6.3 billion. Research and development expenses are expected to be in the range of $5.6 billion to $5.9 billion.

Operating margin, defined as operating income as a percent of revenue, is expected to be 31 percent on a non-GAAP basis in 2020.

Other income (expense) is expected to be expense in the range of $100 million and $250 million.

The 2020 effective tax rate is expected to be approximately 15 percent on both a reported basis and on a non-GAAP basis.

The following table summarizes the company’s 2020 financial guidance.

 
2020 Guidance
 
 
Revenue
$23.6 to $24.1 billion
 
 
 
 
 
 
Gross Margin % of Revenue (reported)
Approx. 79%
 
 
Gross Margin % of Revenue (non-GAAP)
Approx. 81%
 
 
 
 
 
 
Marketing, Selling & Administrative
$6.1 to $6.3 billion
 
 
 
 
 
 
Research & Development
$5.6 to $5.9 billion
 
 
 
 
 
 
Other Income/(Expense)
$(250) to $(100) million
 
 
 
 
 
 
Tax Rate
Approx. 15%
 
 
 
 
 
 
Earnings per share (reported)
$6.38 to $6.48
 
 
Earnings per share (non-GAAP)
$6.70 to $6.80
 
 
 
 
 
 
Operating Income % of Revenue (non-GAAP)
31%
 
 
Non-GAAP guidance reflects adjustments presented in the earnings per share table above.

Webcast of Conference Call
As previously announced, investors and the general public can access a live webcast of the 2020 financial guidance conference call through a link on Lilly’s website at www.lilly.com. The conference call will begin at 9:00 a.m. Eastern time (ET) today and will be available for replay via the website.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY

This press release contains management’s current intentions and expectations for the future, all of which are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees that pipeline products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company’s results may also be affected by such factors as the timing of anticipated regulatory approvals and launches of new products; market uptake of recently launched products; competitive developments affecting current products and our pipeline; the expiration of intellectual property protection for certain of the company’s products; the company’s ability to protect and enforce patents and other intellectual property; the impact of actions of governmental and private payers affecting the pricing of, reimbursement for, and access to pharmaceuticals; regulatory compliance problems or government investigations; regulatory actions regarding currently marketed products; unexpected safety or efficacy concerns associated with the company’s products; issues with product supply stemming from manufacturing difficulties or disruptions; regulatory changes or other developments; changes in patent law or regulations related to data-package exclusivity; litigation involving past, current or future products; unauthorized disclosure, misappropriation, or compromise of trade secrets or other confidential data stored in the company’s information systems, networks and facilities, or those of third parties with which the company shares its data; changes in tax law and regulations, including the impact of U.S. tax reform legislation enacted in December 2017 and related guidance; changes in inflation, interest rates, and foreign currency exchange rates; asset impairments and restructuring charges; changes in accounting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); acquisitions and business development transactions and related integration costs; information technology system inadequacies or operating failures; reliance on third-party relationships and outsourcing arrangements; and global macroeconomic conditions. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company’s latest Form 10-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.
#    #    #
        
Baqsimi™ (glucagon, Lilly)
Basaglar® (insulin glargine injection, Lilly)
Cyramza® (ramucirumab, Lilly)
Emgality® (galcanezumab-gnlm, Lilly)
Forteo® (teriparatide of recombinant DNA origin injection, Lilly)
Jardiance® (empagliflozin, Boehringer Ingelheim)
Olumiant® (baricitinib, Lilly)
REYVOW™ (lasmiditan, Lilly)
Taltz® (ixekizumab, Lilly)
Trulicity® (dulaglutide, Lilly)
Verzenio® (abemaciclib, Lilly)

 EX-101.SCH 3 lly-20191217.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 lly-20191217_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 lly-20191217_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 lly-20191217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Information [Table] Document Information [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock (no par value) Common Class A [Member] 1.000% Notes due 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 lly-20191217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 lilly2020financialgui_image1.gif begin 644 lilly2020financialgui_image1.gif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end XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 9 97 1 false 8 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.lilly.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports a8-k2020guidancedecemb.htm lilly2020financialguid.htm lly-20191217.xsd lly-20191217_cal.xml lly-20191217_def.xml lly-20191217_lab.xml lly-20191217_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 11 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
Dec. 17, 2019
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 17, 2019
Entity Incorporation, State or Country Code IN
Entity File Number 001-06351
Entity Tax Identification Number 35-0470950
Entity Address, Address Line One Lilly Corporate Center
Entity Address, City or Town Indianapolis
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46285
City Area Code 317
Local Phone Number 276-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Registrant Name ELI LILLY AND COMPANY
Entity Central Index Key 0000059478
Amendment Flag false
Common Stock (no par value)  
Document Information [Line Items]  
Title of 12(b) Security Common Stock (no par value)
Trading Symbol LLY
Security Exchange Name NYSE
1.000% Notes due 2022  
Document Information [Line Items]  
Title of 12(b) Security 1.000% Notes due 2022
Trading Symbol LLY22
Security Exchange Name NYSE
7 1/8% Notes due 2025  
Document Information [Line Items]  
Title of 12(b) Security 7 1/8% Notes due 2025
Trading Symbol LLY25
Security Exchange Name NYSE
1.625% Notes due 2026  
Document Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2026
Trading Symbol LLY26
Security Exchange Name NYSE
2.125% Notes due 2030  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Notes due 2030
Trading Symbol LLY30
Security Exchange Name NYSE
0.625% Notes due 2031  
Document Information [Line Items]  
Title of 12(b) Security 0.625% Notes due 2031
Trading Symbol LLY31
Security Exchange Name NYSE
6.77% Notes due 2036  
Document Information [Line Items]  
Title of 12(b) Security 6.77% Notes due 2036
Trading Symbol LLY36
Security Exchange Name NYSE
1.700% Notes due 2049  
Document Information [Line Items]  
Title of 12(b) Security 1.700% Notes due 2049
Trading Symbol LLY49A
Security Exchange Name NYSE
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 a8-k2020guidancedecemb_htm.xml IDEA: XBRL DOCUMENT 0000059478 2019-12-17 2019-12-17 0000059478 us-gaap:CommonClassAMember 2019-12-17 2019-12-17 0000059478 lly:A625Notesdue2031Member 2019-12-17 2019-12-17 0000059478 lly:A1.625NotesDueJune22026Member 2019-12-17 2019-12-17 0000059478 lly:A1.700Notesdue2049Member 2019-12-17 2019-12-17 0000059478 lly:A2.125NotesDueJune32030Member 2019-12-17 2019-12-17 0000059478 lly:A718NotesDueJune12025Member 2019-12-17 2019-12-17 0000059478 lly:A6.77NotesDueJanuary12036Member 2019-12-17 2019-12-17 0000059478 lly:A1.000NotesDueJune22022Member 2019-12-17 2019-12-17 false 0000059478 8-K 2019-12-17 ELI LILLY AND COMPANY IN 001-06351 35-0470950 Lilly Corporate Center Indianapolis IN 46285 317 276-2000 false false false false false Common Stock (no par value) LLY NYSE 1.000% Notes due 2022 LLY22 NYSE 7 1/8% Notes due 2025 LLY25 NYSE 1.625% Notes due 2026 LLY26 NYSE 2.125% Notes due 2030 LLY30 NYSE 0.625% Notes due 2031 LLY31 NYSE 6.77% Notes due 2036 LLY36 NYSE 1.700% Notes due 2049 LLY49A NYSE JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8-k2020guidancedecemb.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 9, "dts": { "calculationLink": { "local": [ "lly-20191217_cal.xml" ] }, "definitionLink": { "local": [ "lly-20191217_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a8-k2020guidancedecemb.htm" ] }, "labelLink": { "local": [ "lly-20191217_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lly-20191217_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lly-20191217.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 7, "memberStandard": 1, "nsprefix": "lly", "nsuri": "http://www.lilly.com/20191217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-k2020guidancedecemb.htm", "contextRef": "D2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.lilly.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-k2020guidancedecemb.htm", "contextRef": "D2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 8, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "lly_A1.000NotesDueJune22022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.000% Notes Due June 2, 2022 [Member]", "label": "1.000% Notes Due June 2, 2022 [Member]", "terseLabel": "1.000% Notes due 2022" } } }, "localname": "A1.000NotesDueJune22022Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1.625NotesDueJune22026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.625% Notes Due June 2, 2026 [Member]", "label": "1.625% Notes Due June 2, 2026 [Member]", "terseLabel": "1.625% Notes due 2026" } } }, "localname": "A1.625NotesDueJune22026Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1.700Notesdue2049Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.700% Notes due 2049 [Member]", "label": "1.700% Notes due 2049 [Member]", "terseLabel": "1.700% Notes due 2049" } } }, "localname": "A1.700Notesdue2049Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A2.125NotesDueJune32030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.125% Notes Due June 3, 2030 [Member]", "label": "2.125% Notes Due June 3, 2030 [Member]", "terseLabel": "2.125% Notes due 2030" } } }, "localname": "A2.125NotesDueJune32030Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A6.77NotesDueJanuary12036Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "6.77% Notes Due January 1, 2036 [Member]", "label": "6.77% Notes Due January 1, 2036 [Member]", "terseLabel": "6.77% Notes due 2036" } } }, "localname": "A6.77NotesDueJanuary12036Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A625Notesdue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": ".625% Notes due 2031 [Member]", "label": ".625% Notes due 2031 [Member]", "terseLabel": "0.625% Notes due 2031" } } }, "localname": "A625Notesdue2031Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A718NotesDueJune12025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "7 1/8% Notes Due June 1, 2025 [Member]", "label": "7 1/8% Notes Due June 1, 2025 [Member]", "terseLabel": "7 1/8% Notes due 2025" } } }, "localname": "A718NotesDueJune12025Member", "nsuri": "http://www.lilly.com/20191217", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Stock (no par value)" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000059478-19-000322-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000059478-19-000322-xbrl.zip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end